Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Duesbery

Showing results (31-40 of 68) with videos related to

Pageof 7
Sort By:
Oncogene|February 27, 2007
MKK signaling and vascularizationP E Depeille, Y Ding, J L Bromberg-White, et al.
Clinical & Developmental Immunology|July 18, 2013
A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitroGuipeng Ding, Ximin Chen, Jin Zhu, et al.
Investigative Ophthalmology & Visual Science|October 13, 2011
Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxinJennifer L Bromberg-White, Elissa Boguslawski, Daniel Hekman, et al.
Investigative Ophthalmology & Visual Science|September 5, 2013
Identification of VEGF-independent cytokines in proliferative diabetic retinopathy vitreousJennifer L Bromberg-White, Louis Glazer, Robert Downer, et al.
The Journal of Biological Chemistry|December 19, 2002
Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alphaSung O Kim, Qing Jing, Kasper Hoebe, et al.
The Journal of Biological Chemistry|October 7, 2004
Involvement of domain II in toxicity of anthrax lethal factorXudong Liang, John J Young, Sherrie A Boone, et al.
Current Protein & Peptide Science|October 9, 2002
Anthrax fusion protein therapy of cancerArthur E Frankel, Bayard L Powell, Nick S Duesbery, et al.
Cancer Research Communications|April 17, 2026
Association between diagnostic history and cancer incidence within 5 years: a real-world observational analysisMd Ashad Alam, Grace Williams, Muhammad G Kibriya, et al.
International Journal of Oncology|May 9, 2015
Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgraftsNicholas J Andersen, Elissa B Boguslawski, Cynthia Y Kuk, et al.
Cell Cycle (Georgetown, Tex.)|February 5, 2008
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacyRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Pageof 7

Showing results (31-40 of 68) with videos related to

Sort By:
Pageof 7
Oncogene|February 27, 2007
MKK signaling and vascularizationP E Depeille, Y Ding, J L Bromberg-White, et al.
Clinical & Developmental Immunology|July 18, 2013
A human/murine chimeric fab antibody neutralizes anthrax lethal toxin in vitroGuipeng Ding, Ximin Chen, Jin Zhu, et al.
Investigative Ophthalmology & Visual Science|October 13, 2011
Persistent inhibition of oxygen-induced retinal neovascularization by anthrax lethal toxinJennifer L Bromberg-White, Elissa Boguslawski, Daniel Hekman, et al.
Investigative Ophthalmology & Visual Science|September 5, 2013
Identification of VEGF-independent cytokines in proliferative diabetic retinopathy vitreousJennifer L Bromberg-White, Louis Glazer, Robert Downer, et al.
The Journal of Biological Chemistry|December 19, 2002
Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alphaSung O Kim, Qing Jing, Kasper Hoebe, et al.
The Journal of Biological Chemistry|October 7, 2004
Involvement of domain II in toxicity of anthrax lethal factorXudong Liang, John J Young, Sherrie A Boone, et al.
Current Protein & Peptide Science|October 9, 2002
Anthrax fusion protein therapy of cancerArthur E Frankel, Bayard L Powell, Nick S Duesbery, et al.
Cancer Research Communications|April 17, 2026
Association between diagnostic history and cancer incidence within 5 years: a real-world observational analysisMd Ashad Alam, Grace Williams, Muhammad G Kibriya, et al.
International Journal of Oncology|May 9, 2015
Combined inhibition of MEK and mTOR has a synergic effect on angiosarcoma tumorgraftsNicholas J Andersen, Elissa B Boguslawski, Cynthia Y Kuk, et al.
Cell Cycle (Georgetown, Tex.)|February 5, 2008
Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacyRandall W Alfano, Stephen H Leppla, Shihui Liu, et al.
Pageof 7